Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, adding two marketed pain-management drugs to a company that reported negative revenue growth of 3.0 percent in fiscal 2025. The deal, expected to close by year-end 2026, marks a strategic pivot toward higher-margin specialty medicines after years of contraction in Viatris’s core generic business.
Pacira generated approximately $746 million in total revenue and approximately $177 million in adjusted EBITDA during the last twelve months ended June 30, 2026. Viatris will fund the transaction primarily from excess cash with the remainder from short-term borrowings, and the company expects minimal impact on its gross leverage ratio. The interim CFO stated the acquisition is expected to be immediately accretive to Viatris’s financial guidance metrics, though the company did not raise, cut, or reaffirm forward guidance in this filing.
What it means
The acquisition targets a structural problem: Viatris’s operating margin collapsed to negative 18.7 percent in fiscal 2025, a sign that generic-drug pricing pressure and manufacturing costs have eroded profitability faster than the company can cut overhead. Pacira’s two drugs, EXPAREL for postsurgical pain and ZILRETTA for osteoarthritis, carry patent protection and higher gross margins than generics, offering a partial escape from that margin trap. Pacira’s $177 million adjusted EBITDA on $746 million revenue implies an EBITDA margin near 24 percent, roughly 10 times Viatris’s operating margin in the same period.
The deal is synergistic with Viatris’s existing fast-acting meloxicam program, suggesting the company sees a portfolio of non-opioid pain therapies as defensible against commoditization. However, the filing does not disclose the purchase price multiple (enterprise value to EBITDA), the amount of debt Viatris will incur, or how much of the $1.65 billion equity value represents a premium to Pacira’s trading price. The claim that the deal preserves financial flexibility cannot be tested without knowing Viatris’s current cash position and debt covenants.
The open question is whether Viatris can sustain Pacira’s margin profile after integration. The company states it will “leverage its intellectual property expertise and proven ability to extend product lifecycles” after generic entry, a euphemism for managing decline. That strategy works only if Pacira’s products face years of patent protection remaining; the filing does not disclose expiration dates for EXPAREL or ZILRETTA patents.
What to watch
Viatris will report third-quarter 2026 results and host a conference call on November 5, 2026, at 8:30 a.m. ET. That filing will include updated full-year guidance and detail on debt financing for the Pacira deal. The company’s next quarterly earnings report will show whether integration costs offset the claimed accretion to guidance metrics.
Source: the company’s 8-K filed 2026-10-08 with the SEC.
For the standing yardsticks on Viatris: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Viatris.
